Literature DB >> 1700422

A monoclonal antibody that neutralizes Epstein-Barr virus, human cytomegalovirus, human herpesvirus 6, and bacteriophage T4 DNA polymerases.

C H Tsai1, M V Williams, R Glaser.   

Abstract

A monoclonal antibody (mAb) designated 55H3 was produced by using chemically induced Epstein-Barr virus genome-positive B95-8 cells. mAb 55H3, which reacted with an 85- to 80-kDa polypeptide, neutralized Epstein-Barr virus-encoded DNA polymerase activity in crude extracts of chemically induced M-ABA, HR-1, and B95-8 cells, as well as the partially purified Epstein-Barr virus DNA polymerase in a dose-dependent manner. The mAb also neutralized the virus-encoded DNA polymerase activity from cells infected with human cytomegalovirus, human herpesvirus 6, and the purified bacteriophage T4 DNA polymerases. However, mAb 55H3 did not neutralize the DNA polymerase activities encoded for by herpes simplex virus types 1 and 2, the reverse transcriptase of avian myeloblastosis virus, or Escherichia coli DNA polymerase 1 (Klenow fragment). These results suggest that mAb 55H3 recognizes an epitope common to some herpesviruses and T4 DNA polymerases and further supports the hypothesis that these organisms are evolutionarily related.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1700422      PMCID: PMC54872          DOI: 10.1073/pnas.87.20.7963

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Enhanced endothelial cytopathogenicity induced by a cytomegalovirus strain propagated in endothelial cells.

Authors:  W J Waldman; J M Sneddon; R E Stephens; W H Roberts
Journal:  J Med Virol       Date:  1989-08       Impact factor: 2.327

2.  Predilection of a nasopharyngeal carcinoma-derived isolate of Epstein-Barr virus for infection of specific subsets of B lymphocytes.

Authors:  K L Tarr; R Glaser
Journal:  J Med Virol       Date:  1989-09       Impact factor: 2.327

3.  Purification of Epstein-Barr virus DNA polymerase from P3HR-1 cells.

Authors:  B Kallin; L Sternås; A K Saemundssen; J Luka; H Jörnvall; B Eriksson; P Z Tao; M T Nilsson; G Klein
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

4.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

Review 5.  The biology and chemistry of Epstein-Barr virus.

Authors:  E Kieff; T Dambaugh; M Heller; W King; A Cheung; V van Santen; M Hummel; C Beisel; S Fennewald; K Hennessy; T Heineman
Journal:  J Infect Dis       Date:  1982-10       Impact factor: 5.226

6.  Sequence and transcription analysis of the human cytomegalovirus DNA polymerase gene.

Authors:  T Kouzarides; A T Bankier; S C Satchwell; K Weston; P Tomlinson; B G Barrell
Journal:  J Virol       Date:  1987-01       Impact factor: 5.103

7.  A monoclonal antibody that neutralizes Epstein-Barr virus DNA polymerase activity.

Authors:  C H Tsai; M V Williams; R Glaser
Journal:  Intervirology       Date:  1990       Impact factor: 1.763

8.  Demonstration of the human herpesvirus 6-induced DNA polymerase and DNase.

Authors:  M V Williams; D V Ablashi; S Z Salahuddin; R Glaser
Journal:  Virology       Date:  1989-11       Impact factor: 3.616

9.  Genetic evidence for vaccinia virus-encoded DNA polymerase: isolation of phosphonoacetate-resistant enzyme from the cytoplasm of cells infected with mutant virus.

Authors:  B Moss; N Cooper
Journal:  J Virol       Date:  1982-08       Impact factor: 5.103

10.  Yet another improved silver staining method for the detection of proteins in polyacrylamide gels.

Authors:  P Tunón; K E Johansson
Journal:  J Biochem Biophys Methods       Date:  1984-05
View more
  1 in total

1.  Characterization of the DNA polymerase gene of human herpesvirus 6.

Authors:  I A Teo; B E Griffin; M D Jones
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.